SCHEMBL3196242

SCHEMBL3196242

ClCc1cc(Cl)ccc1Sc1ccc(Cl)cc1CCl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 4/20 0.46
CYP3A4 P08684 4/20 0.45
CYP2C9 P11712 4/20 0.45
HIF1A Q16665 3/20 0.45
KMT2A Q03164 3/20 0.45
HPGD P15428 3/20 0.45
HTT P42858 3/20 0.45
CYP2C19 P33261 3/20 0.45
MEN1 O00255 2/20 0.45
HSP90AA1 P07900 2/20 0.45
ALOX15 P16050 2/20 0.45
PLA2G1B P04054 2/20 0.45
CYP2D6 P10635 2/20 0.45
ATG4B Q9Y4P1 2/20 0.45
ALDH1A1 P00352 1/20 0.45
HSD17B10 Q99714 1/20 0.45
SLC6A2 P23975 3/20 0.42
SLC6A3 Q01959 3/20 0.42
ITGB2 P05107 3/20 0.42
ICAM1 P05362 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11758917 0.88 MEN1 (0.50) SLC6A4CYP3A4CYP2C9KMT2AHPGD
SCHEMBL6299244 0.83 SLC6A4 (0.44) SLC6A4CYP3A4CYP2C9HIF1AKMT2A
SCHEMBL11757703 0.82 SLC6A4 (0.44) SLC6A4CYP3A4CYP2C9KMT2AHPGD
SCHEMBL11759797 0.82 MEN1 (0.44) SLC6A4CYP3A4CYP2C9KMT2AHPGD
SCHEMBL7318881 0.81 HIF1A (0.41) SLC6A4CYP3A4CYP2C9HIF1AKMT2A
SCHEMBL4440726 0.80 SLC6A4 (0.66) SLC6A4CYP3A4CYP2C9HIF1AKMT2A
SCHEMBL11760048 0.78 SLC6A4 (0.43) SLC6A4PLA2G1BATG4BSLC6A2SLC6A3
SCHEMBL11759836 0.78 IDO1 (0.53) SLC6A4KMT2ASLC6A2SLC6A3IDO1
SCHEMBL15653298 0.77 IDO1 (0.40) CYP3A4CYP2C9HIF1AKMT2AHPGD
SCHEMBL15653495 0.77 IDO1 (0.40) CYP3A4CYP2C9HIF1AKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035951-A1 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2010-02-11 US disclosed
EP-2041096-A1 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL- CONDUCTANCE CALCIUM-ACTIVATED POTATIUM CHANNELS NeuroSearch AS (DK) 2009-04-01 EP disclosed
WO-2008003752-A1 2 -AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL - CONDUCTANCE CALCIUM -ACT IVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035951-A1 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS KCNN2, KCNN1, KCNN3 SLC6A4 1050/4885CYP3A4 1188/4885CYP2C9 1851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.